{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:10:57Z","timestamp":1793315457352,"version":"4.5.0"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Glucocorticoids remain among the most widely prescribed immunosuppressive and anti-inflammatory agents worldwide, yet their clinical use is complicated by substantial inter-individual variability in both therapeutic response and adverse effects. Despite decades of clinical experience, glucocorticoid prescribing remains largely empirical, with limited integration of precision medicine approaches that could optimize therapeutic outcomes while minimizing toxicity. This review synthesizes current evidence on emerging precision approaches to glucocorticoid therapy across three key domains: pharmacogenomic determinants (including variants in NR3C1, FKBP5, CYP3A4\/5, and ABCB1) that modulate immune cell responsiveness to glucocorticoids; pharmacokinetic variability and model-informed precision dosing strategies; and disease-specific biomarker-guided approaches across major immune-mediated conditions including respiratory diseases, rheumatologic conditions, inflammatory bowel disease, polymyalgia rheumatica, and critical illness. Genetic variants in glucocorticoid receptor signaling and drug metabolism pathways have suggested some associations with treatment response and adverse effects, although none are yet acknowledged as clinically actionable by consensus resources. Disease-specific immunological biomarkers including eosinophil counts, inflammatory cytokines, and pharmacodynamic endpoints suggest the promise of individualized dose optimization. Risk stratification for glucocorticoid-induced osteoporosis\u2014mediated through OPG\/RANKL signaling and monocyte-osteoclast crosstalk\u2014incorporating both clinical factors and pharmacogenetic markers may facilitate targeted prevention strategies. The integration of pharmacogenomic testing, immune biomarker monitoring, and pharmacokinetic modeling represents an aspirational paradigm shift from empirical dosing to individualized immunomodulatory therapy. It should be acknowledged that, as of the time of writing, this precision framework remains largely investigational: routine clinical practice continues to rely predominantly on indication-specific regimens and empirical tapering protocols. This review is explicitly forward-looking, aiming to outline a research agenda for precision glucocorticoid therapy in immune-mediated diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1889058","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:32:46Z","timestamp":1787567566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The aspiration of precision glucocorticoid pharmacotherapy in immune-mediated diseases: where do we stand in integrating pharmacogenomics and biomarkers for individualized treatment?"],"prefix":"10.3389","volume":"17","author":[{"given":"Matteo","family":"Colina","sequence":"first","affiliation":[{"name":"Rheumatology Service, Section of Internal Medicine - Department of Medicine and Oncology - Ospedale Santa Maria della Scaletta","place":["Imola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Campana","sequence":"additional","affiliation":[{"name":"Alma Mater Studiorum, Department of Pharmacy and Biotechnology, University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-14-71","article-title":"Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor","volume":"14","author":"Nicolaides","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(24)00526-3","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench","year":"1949","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M","article-title":"A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited","volume":"41","author":"Buttgereit","year":"1998","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids--new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jsbmb.2010.03.058","article-title":"The role of the glucocorticoid receptor in inflammation and immunity","volume":"120","author":"Baschant","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619894147","article-title":"Precision dosing to avoid adverse drug reactions","volume":"10","author":"Polasek","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21037\/jlpm-25-9","article-title":"A review of pharmacogenomics in the individualization of pharmacological treatment: present and future","volume":"11","author":"Marques-Garcia","year":"2026","journal-title":"J Lab Precis Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00038-019-01298-x","article-title":"Cost-effectiveness of precision medicine: a scoping review","volume":"64","author":"Kasztura","year":"2019","journal-title":"Int J Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.051","article-title":"Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions","volume":"106","author":"Klein","year":"2017","journal-title":"J Pharm Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/er.2014-1010","article-title":"Comprehensive overview of the structure and regulation of the glucocorticoid receptor","volume":"35","author":"Vandevyver","year":"2014","journal-title":"Endocr Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1210\/en.2012-2045","article-title":"New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation","volume":"154","author":"Vandevyver","year":"2013","journal-title":"Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16100","article-title":"A guide to changing paradigms of glucocorticoid receptor function-a model system for genome regulation and physiology","volume":"289","author":"Vettorazzi","year":"2022","journal-title":"FEBS J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020970","article-title":"11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids","volume":"87","author":"Diederich","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-012-0007-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation","volume":"51","author":"Bergmann","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2011.02.053","article-title":"New insights into corticosteroid-binding globulin and glucocorticoid delivery","volume":"180","author":"Henley","year":"2011","journal-title":"Neuroscience"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2023.01.002","article-title":"Corticosteroid-binding globulin (CBG): spatiotemporal distribution of cortisol in sepsis","volume":"34","author":"Lee","year":"2023","journal-title":"Trends Endocrinol Metab TEM"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.046318","article-title":"Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes","volume":"41","author":"Moore","year":"2013","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13645","article-title":"In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance","volume":"129","author":"Skauby","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"373","author":"Barnes","year":"2009","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0067","article-title":"Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies","volume":"90","author":"Chriguer","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910839","article-title":"Primary generalized glucocorticoid resistance and hypersensitivity syndromes: a 2021 update","volume":"22","author":"Nicolaides","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202105-1302OC","article-title":"Latent class analysis reveals COVID-19\u2013related acute respiratory distress syndrome subgroups with differential responses to corticosteroids","volume":"204","author":"Sinha","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/rp.59.1.333","article-title":"Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition","volume":"59","author":"van Rossum","year":"2004","journal-title":"Recent Prog Horm Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0646","article-title":"Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression","volume":"90","author":"Russcher","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162437","article-title":"Analysis of BCLI, N363S and ER22\/23EK polymorphisms of the glucocorticoid receptor gene in adrenal incidentalomas","volume":"11","author":"Reimondo","year":"2016","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.09.007","article-title":"The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease","volume":"132","author":"Oakley","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae151","article-title":"Epigenetic mechanisms modulated by glucocorticoids with a focus on Cushing syndrome","volume":"109","author":"Paes","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbi.2006.08.009","article-title":"Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression","volume":"21","author":"Pace","year":"2007","journal-title":"Brain Behav Immun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221810049","article-title":"Glucocorticoid resistance: interference between the glucocorticoid receptor and the MAPK signalling pathways","volume":"22","author":"Sevilla","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"CD000296","DOI":"10.1002\/14651858.CD000296.pub4","article-title":"Budesonide for induction of remission in Crohn\u2019s disease","volume":"2015","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst. Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"B40","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060635","article-title":"Development of a multi-biomarker disease activity test for rheumatoid arthritis","volume":"8","author":"Centola","year":"2013","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/bmj.38398.500764.8F","article-title":"Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success","volume":"330","author":"Kawamoto","year":"2005","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-015-1618-x","article-title":"Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis: a meta-analysis","volume":"75","author":"Lee","year":"2016","journal-title":"Z Rheumatol"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","volume-title":"Drug Transporters","author":"Cascorbi","year":"2011"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/BOR.0b013e32835fad45","article-title":"Musculoskeletal ultrasound and other imaging modalities in rheumatoid arthritis","volume":"25","author":"Ohrndorf","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep339","article-title":"The detection of subclinical synovitis by ultrasound in oligoarticular juvenile idiopathic arthritis: a pilot study","volume":"49","author":"Haslam","year":"2010","journal-title":"Rheumatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004269","article-title":"Persistence of power doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study","volume":"10","author":"Mouterde","year":"2024","journal-title":"RMD Open"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123950","article-title":"MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression","volume":"70","author":"B\u00f8yesen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B51","unstructured":"London\n          National Institute for Health and Care Excellence (NICE\n          Treat-to-Target: Rheumatoid Arthritis in Adults: Diagnosis and Management: Evidence Review C\n          \n          2018"},{"key":"B52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clim.2017.07.019","article-title":"Biomarkers as a treatment guide in rheumatoid arthritis","volume":"186","author":"Takeuchi","year":"2018","journal-title":"Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.24772","article-title":"Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint disease activity score, C-reactive protein level and patient global assessment","volume":"74","author":"Felson","year":"2022","journal-title":"Arthritis Care Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014899","article-title":"Long\u2010term glucocorticoids for rheumatoid arthritis","volume":"2021","author":"McKenzie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B57","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers","year":"2005","journal-title":"J Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.23338","article-title":"Performance of the polymyalgia rheumatica activity score for diagnosing disease flares","volume":"59","author":"Binard","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2000.8366","article-title":"Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study","volume":"30","author":"Cantini","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep303a","article-title":"BSR and BHPR guidelines for the management of polymyalgia rheumatica","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep286","article-title":"Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica","volume":"48","author":"Macchioni","year":"2009","journal-title":"Rheumatology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207395","article-title":"Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids","volume":"74","author":"Mackie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae003","article-title":"Characterising polymyalgia rheumatica on whole-body 18F-FDG PET\/CT: an atlas","volume":"8","author":"Owen","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.5414\/CP203901","article-title":"Methotrexate for treating polymyalgia rheumatica: a meta-analysis of randomized controlled trials","volume":"59","author":"Song","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"B69","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2026.152955","article-title":"Is there a window of opportunity in the treatment of giant cell arteritis with tocilizumab? Multicenter study of 471 patients","volume":"78","author":"Mart\u00edn-Guti\u00e9rrez","year":"2026","journal-title":"Semin Arthritis Rheum"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3390\/ijms26062503","article-title":"Gut microbiota serves as a crucial independent biomarker in inflammatory bowel disease (IBD)","volume":"26","author":"Sharma","year":"2025","journal-title":"Int. J. Mol. Sci"},{"key":"B73","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12876-025-04035-2","article-title":"Predictive accuracy of fecal calprotectin in assessing clinical activity and disease severity in patients with ulcerative colitis and crohn\u2019s disease","volume":"25","author":"Jain","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae167","article-title":"Impact of histological remission for predicting clinical relapse in Crohn\u2019s disease: a post hoc analysis of the prospective STORI cohort","volume":"19","author":"Reenaers","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.14309\/ajg.0000000000003339","article-title":"Fecal calprotectin correlates with disease extent but remains a reliable marker of mucosal healing in ulcerative colitis","volume":"120","author":"Steinsb\u00f8","year":"2025","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwz006.120","article-title":"A121 lack of CRP response in Crohn\u2019s disease associated with lower rates of biologic therapy: results of a single center case-control study","volume":"2","author":"Nero","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073717","article-title":"Genetic variants associated with biological treatment response in inflammatory bowel disease: a systematic review","volume":"25","author":"Plaza","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11894-025-00991-7","article-title":"Applying biomarkers in treat-to-target approach for IBD","volume":"27","author":"Lutz","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i13.3475","article-title":"Therapeutic drug monitoring in patients with inflammatory bowel disease","volume":"20","author":"Yarur","year":"2014","journal-title":"World J Gastroenterol WJG"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3673-1","article-title":"Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of Crohn\u2019s disease: avoiding failure while lowering costs","volume":"60","author":"Vande Casteele","year":"2015","journal-title":"Dig Dis Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.05.015","article-title":"An international consensus on appropriate management of corticosteroids in clinical trials in inflammatory bowel disease","volume":"169","author":"Han\u017eel","year":"2025","journal-title":"Gastroenterology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000209791.98866.ba","article-title":"Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study","volume":"12","author":"Onnie","year":"2006","journal-title":"Inflammation Bowel Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/92936","article-title":"The importance of the polymorphisms of the ABCB1 gene in disease susceptibility, behavior and response to treatment in inflammatory bowel disease: a literature review","volume":"27","author":"Petryszyn","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.681907","article-title":"Thiopurines in inflammatory bowel disease. How to optimize thiopurines in the biologic era","volume":"8","author":"Gargallo-Puyuelo","year":"2021","journal-title":"Front Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(98)00416-X","article-title":"Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease","volume":"93","author":"Straub","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/00042737-200505000-00012","article-title":"Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome","volume":"17","author":"Raddatz","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07841-3","article-title":"Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response","volume":"10","author":"Haberman","year":"2019","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30232-6","article-title":"Neutrophilic asthma: a distinct target for treatment","volume":"4","author":"Chung","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.002","article-title":"Mechanisms of non-type 2 asthma","volume":"66","author":"Hudey","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200610-1427OC","article-title":"The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial","volume":"176","author":"Shaw","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thx.2010.135574","article-title":"A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)","volume":"67","author":"Petsky","year":"2012","journal-title":"Thorax"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911353","article-title":"Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma","volume":"365","author":"Tantisira","year":"2011","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.11.177","article-title":"Variation at GLCCI1 and FCER2: one step closer to personalized asthma treatment","volume":"13","author":"Maitland-van der Zee","year":"2012","journal-title":"Pharmacogenomics"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.09.005","article-title":"FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma","volume":"120","author":"Tantisira","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B106","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease\n          \n          2023"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.6.9903114","article-title":"Induced sputum eicosanoid concentrations in asthma","volume":"160","author":"Pavord","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the sledai. A disease activity index for lupus patients","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.11.661","article-title":"The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation","volume":"56","author":"Bootsma","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2350::AID-ART398>3.0.CO;2-A","article-title":"A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus","volume":"44","author":"Ho","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/321359","article-title":"Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects","volume":"2014","author":"Cozzani","year":"2014","journal-title":"Autoimmune Dis"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004080658","article-title":"Urine chemokines as biomarkers of human systemic lupus erythematosus activity","volume":"16","author":"Rovin","year":"2005","journal-title":"J Am Soc Nephrol JASN"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25684","article-title":"The renal activity index for lupus identifies active renal disease and treatment response in adult patients with systemic lupus erythematosus and lupus nephritis","author":"Brunner","year":"2025","journal-title":"Arthritis Care Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/638413","article-title":"Biomarkers for lupus nephritis: a critical appraisal","volume":"2010","author":"Mok","year":"2010","journal-title":"BioMed Res Int"},{"key":"B118","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ajhg.2012.11.013","article-title":"Genomic pathology of SLE-associated copy-number variation at the FCGR2C\/FCGR3B\/FCGR2B locus","volume":"92","author":"Mueller","year":"2013","journal-title":"Am J Hum Genet"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/sj.tpj.6500462","article-title":"The clinical role of genetic polymorphisms in drug-metabolizing enzymes","volume":"8","author":"Tomalik-Scharte","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1651","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160030","article-title":"Integrating pharmacogenomics into electronic health records with clinical decision support","volume":"73","author":"Hicks","year":"2016","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"key":"B122","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpt.2387","article-title":"Pharmacogenomic clinical decision support: a review, how-to guide, and future vision","volume":"112","author":"Wake","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-8-117","article-title":"The dynamic sustainability framework: addressing the paradox of sustainment amid ongoing change","volume":"8","author":"Chambers","year":"2013","journal-title":"Implement Sci IS"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/art.42646","article-title":"2022 american college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12020-018-1588-2","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"61","author":"Compston","year":"2018","journal-title":"Endocrine"},{"key":"B127","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00240-9","article-title":"Attributable cost of adult hospitalized pneumonia beyond the acute phase","volume":"5","author":"Weycker","year":"2021","journal-title":"PharmacoEcon Open"},{"key":"B129","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker","year":"2023","journal-title":"Diabetes Care"},{"key":"B130","article-title":"US cost burden of ischemic stroke: a systematic literature review","volume":"16","author":"Demaerschalk","year":"2010","journal-title":"Am J Manag Care"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B134","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/367284a0","article-title":"Prediction of bone density from vitamin D receptor alleles","volume":"367","author":"Morrison","year":"1994","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804093381502","article-title":"Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women","volume":"338","author":"Uitterlinden","year":"1998","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/ng1096-203","article-title":"Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene","volume":"14","author":"Grant","year":"1996","journal-title":"Nat Genet"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.17.2105","article-title":"Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes","volume":"292","author":"Ioannidis","year":"2004","journal-title":"JAMA"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1086\/420771","article-title":"Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites","volume":"74","author":"Ferrari","year":"2004","journal-title":"Am J Hum Genet"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar","year":"2019","journal-title":"N Engl J Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B150","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.japh.2019.10.003","article-title":"Coverage of pharmacogenetic tests by private health insurance companies","volume":"60","author":"Park","year":"2020","journal-title":"J Am Pharm Assoc JAPhA"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1179364","article-title":"Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States","volume":"14","author":"Lemke","year":"2023","journal-title":"Front Pharmacol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0316-z","article-title":"A guide to deep learning in healthcare","volume":"25","author":"Esteva","year":"2019","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"283rv3","DOI":"10.1126\/scitranslmed.aaa3487","article-title":"The emerging field of mobile health","volume":"7","author":"Steinhubl","year":"2015","journal-title":"Sci Transl Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601705","article-title":"State of telehealth","volume":"375","author":"Dorsey","year":"2016","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/b978-1-4160-6164-9.00020-2","article-title":"Existing and emerging technologies for point-of-care testing","volume":"35","author":"St John","year":"2014","journal-title":"Clin Biochem Rev"},{"key":"B159","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.25","article-title":"Metabolomics: beyond biomarkers and towards mechanisms","volume":"17","author":"Johnson","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"B163","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1126\/science.1217876","article-title":"An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people","volume":"337","author":"Nelson","year":"2012","journal-title":"Science"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.306","article-title":"Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey","volume":"91","author":"Stanek","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B167","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41576-020-00306-8","article-title":"African genetic diversity and adaptation inform a precision medicine agenda","volume":"22","author":"Pereira","year":"2021","journal-title":"Nat Rev Genet"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/538161a","article-title":"Genomics is failing on diversity","volume":"538","author":"Popejoy","year":"2016","journal-title":"Nature"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33014","article-title":"The evolving epidemic of breast cancer in sub-Saharan Africa: results from the African Cancer Registry Network","volume":"147","author":"Joko-Fru","year":"2020","journal-title":"Int J Cancer"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0077","article-title":"Patient experiences with pharmacogenetic testing in a primary care setting","volume":"17","author":"Haga","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B172","article-title":"Table of pharmacogenomic biomarkers in drug labeling","year":"2023"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med Off J Am Coll Med Genet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:32:49Z","timestamp":1787567569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":173,"alternative-id":["10.3389\/fimmu.2026.1889058"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1889058","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1889058"}}